---
title: "Solid Therapeutics ApS – Regnskab 2025 og nøgletal"
description: "Solid Therapeutics ApS (CVR 43007068). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -1,7 mio. DKK, årets resultat -4,4 mio. DKK, egenkapital -15,4 mio. DKK."
canonical_url: "https://datapublica.dk/companies/43007068-solid-therapeutics-aps/financials"
locale: "da"
route_type: "company_financials"
robots: "index,follow"
content_access: "standard"
---

# Solid Therapeutics ApS — Regnskab

Solid Therapeutics ApS \(CVR 43007068\). Regnskabsperiode: 2025-01-01 – 2025-12-31. Bruttofortjeneste -1,7 mio. DKK, årets resultat -4,4 mio. DKK, egenkapital -15,4 mio. DKK.

CVR 43007068

## Seneste regnskabsperiode

- 2025 • 2025-01-01 • 2025-12-31 • entity • DKK • -1687751 • -4051662 • -4355625 • 6842364 • -15353766 • 3

## Regnskabshistorik

- 2024 • 2024-01-01 • 2024-12-31 • entity • DKK • -4213656 • -7247059 • -6758207 • 11003832 • -10998141 • 4

- 2023 • 2023-01-01 • 2023-12-31 • entity • DKK • -2738806 • -4193025 • -3483115 • 10813082 • -4239933 • 2

- 2022 • 2022-01-01 • 2022-12-31 • entity • DKK • -398000 • -762000 • -797000 • 3576000 • -757000 • 1

- 2022 • 2022-01-21 • 2022-12-31 • entity • DKK • -397812 • -761682 • -796818 • 3575234 • -756818 • 1

## Højdepunkter fra årsrapporten

- primary activities • The company's object is to engage in activities within pharmaceutical drug discovery and development. • entity

- development in activities and financial affairs • Financial review

The company's income statement for the year ended 31 December 2025 shows a loss of DKK 4.355.625, and the balance sheet at 31 December 2025 shows negative equity of DKK 15.353.766. • entity

- expected development • Expected development of the company, including specific prerequisites and uncertaintiesThe Company has lost its entire share capital. Despite this capital loss, Management assesses that the Company continues to have a sufficient capital base and liquidity to support ongoing operations. Management continuously monitors the capital structure and the potential need to re-establish equity. Together with the Board of Directors, Management is actively working to secure additional funding during the financial year 2026. Furthermore, Management assesses that the Company will obtain the necessary funding to continue its planned operations.

With the grants and loans already secured during 2025, the Company has the financial resources and liquidity to carry out its planned activities for the next 12 months. • entity

- going concern uncertainty • The Company has lost its entire share capital. Despite this capital loss, Management assesses that the Company continues to have a sufficient capital base and liquidity to support ongoing operations. Management continuously monitors the capital structure and the potential need to re-establish equity. Together with the Board of Directors, Management is actively working to secure additional funding during the financial year 2026. Furthermore, Management assesses that the Company will obtain the necessary funding to continue its planned operations.

With the grants and loans already secured during 2025, the Company has the financial resources and liquidity to carry out its planned activities for the next 12 months. • entity

- subsequent events • No events have occurred after the balance sheet date which could significantly affect the company's financial position. • entity

- contingent liabilities • The company has no contingent liabilities. • entity

- mortgages collateral • The company has not provided any security or other collateral at 31 December 2025. • entity